I am inclined to ask what relevance the Hepalink/Cytogance deal from 2 years ago has to do with RVX given that, in broad strokes, RVX is a drug developer and Cytovance is a contract development manufacturing company and not the first one Hepalink has purchased in the US. If the discussion is about whether or not Hepalink would do a milestone based deal you don't have to look any further than the licensing portion of the deal Hepalink has done with RVX. I believe we are set to receive the first $1 million milestone payment of the agreement of which there is apparently the potential for RVX to earn $400 million in sales based milestone payments and royalties.